- Home
- NVCR vs ZLAB Comparison
NVCR vs ZLAB Comparison
Compare NVCR & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVCR
- ZLAB
- Stock Information
- Founded
- NVCR 2000
- ZLAB 2013
- Country
- NVCR Switzerland
- ZLAB China
- Employees
- NVCR N/A
- ZLAB N/A
- Industry
- NVCR Medical/Dental Instruments
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- NVCR Health Care
- ZLAB Health Care
- Exchange
- NVCR Nasdaq
- ZLAB Nasdaq
- Market Cap
- NVCR 1.4B
- ZLAB 3.4B
- IPO Year
- NVCR 2015
- ZLAB 2017
- Fundamental
- Price
- NVCR $12.69
- ZLAB $32.58
- Analyst Decision
- NVCR Buy
- ZLAB Buy
- Analyst Count
- NVCR 7
- ZLAB 6
- Target Price
- NVCR $28.79
- ZLAB $57.22
- AVG Volume (30 Days)
- NVCR 1.4M
- ZLAB 819.9K
- Earning Date
- NVCR 10-29-2025
- ZLAB 11-11-2025
- Dividend Yield
- NVCR N/A
- ZLAB N/A
- EPS Growth
- NVCR N/A
- ZLAB N/A
- EPS
- NVCR N/A
- ZLAB N/A
- Revenue
- NVCR $630,160,000.00
- ZLAB $427,799,000.00
- Revenue This Year
- NVCR $6.68
- ZLAB $42.62
- Revenue Next Year
- NVCR $7.01
- ZLAB $55.12
- P/E Ratio
- NVCR N/A
- ZLAB N/A
- Revenue Growth
- NVCR 14.58
- ZLAB 32.56
- 52 Week Low
- NVCR $10.87
- ZLAB $20.17
- 52 Week High
- NVCR $34.13
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- NVCR 52.68
- ZLAB 48.51
- Support Level
- NVCR $12.08
- ZLAB $31.68
- Resistance Level
- NVCR $12.83
- ZLAB $33.06
- Average True Range (ATR)
- NVCR 0.58
- ZLAB 1.34
- MACD
- NVCR 0.14
- ZLAB 0.21
- Stochastic Oscillator
- NVCR 50.00
- ZLAB 80.97
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.